Targeted Therapy, Immune Cell, and Bispecific Antibody Basics

Targeted Therapy, Immune Cell, and Bispecific Antibody Basics

Targeted therapy is built around a molecular driver: a kinase, surface antigen, DNA-repair defect, or signaling pathway. These agents are oral, subcutaneous, or intravenous and depend on biomarker testing. The RN does not interpret genomics independently but understands why a marker matters, whether the matched drug is accessible, and what monitoring is expected. A targeted drug works only in the matched population: for example, EGFR inhibitors require an EGFR mutation, and HER2 agents require HER2 amplification.

Suffix and Mechanism Decoding

Antibody-drug conjugates (ADCs, e.g., trastuzumab emtansine) link an antibody to a cytotoxic payload, so the RN monitors both reaction and payload-specific toxicity such as neuropathy or ocular effects.

CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy re-engineers the patient's T cells to target an antigen such as CD19. Care spans referral, apheresis, bridging therapy, lymphodepletion, infusion, and prolonged monitoring. Two hallmark toxicities define the safety teaching:

• Cytokine release syndrome (CRS): fever is the entry point; grading escalates with hypotension and hypoxia. Grade 1 is fever alone; higher grades add pressors and oxygen. Tocilizumab (an interleukin-6 receptor blocker) is first-line for significant CRS, with corticosteroids added per protocol.
• ICANS (immune effector cell-associated neurotoxicity syndrome): scored with the Immune Effector Cell-Associated Encephalopathy (ICE) tool. New aphasia, tremor, deteriorating handwriting, confusion, seizure, or somnolence is an emergency; cerebral edema is the feared endpoint.

Bispecific Antibodies

Bispecific antibodies (e.g., teclistamab, blinatumomab) bind one immune-cell target and one cancer-cell target, bridging the two to trigger killing. They cause CRS and neurologic toxicity like cellular therapy and commonly use step-up (priming) dosing, premedication, and inpatient or monitored observation in early cycles. The RN must verify the patient understands that fever after a dose is never routine until evaluated, and that fever plus dizziness, hypoxia, or any speech or cognitive change requires urgent evaluation through the oncology emergency pathway.

Oral Targeted Therapy as a Hazardous Drug

Many targeted agents are continuous oral medications, which makes adherence, food rules, drug interactions, and safe handling central nursing issues. Oral antineoplastics are hazardous drugs: keep them in original containers, do not crush or split unless instructed, wash hands after handling, and have caregivers glove when handling pills. Review missed-dose direction from the label or team, never improvised. Screen for interaction risks: grapefruit and acid-suppressing therapy alter the absorption of several tyrosine kinase inhibitors, and anticoagulants, anticonvulsants, and many supplements change drug levels.

Route interaction concerns to the pharmacist or provider rather than guessing.

Nursing Safety Priorities

The phrase targeted therapy can falsely suggest low risk; these agents are specific in mechanism but broad in consequence. Assess for hypertension, rash, diarrhea, edema, dyspnea, cough that may signal drug-induced pneumonitis, neuropathy, vision change, infection, bleeding, fatigue, mood change, and adherence barriers at each contact. For ADCs, layer payload toxicity onto antibody-reaction monitoring. Teach patients the generic name, the target in plain language, and the symptoms that cannot wait.

For cellular and bispecific therapies, fever paired with dizziness, an oxygen need, or any neurologic change should be treated as a CRS or ICANS emergency until proven otherwise, because both syndromes can progress within hours.

Biomarkers Determine Eligibility

Targeted therapy only works when the target is present, so biomarker testing is inseparable from the drug. Examples the exam favors: EGFR mutation for osimertinib in non-small-cell lung cancer, ALK rearrangement for alectinib, HER2 amplification for trastuzumab and HER2-directed ADCs in breast and gastric cancer, BRAF V600E for dabrafenib plus trametinib in melanoma, and BRCA1/2 mutation for PARP inhibitors in ovarian and breast cancer.

Giving a HER2 agent to a HER2-negative tumor offers no benefit and only exposes the patient to toxicity, which is why the nurse confirms that the relevant marker result is on file before a matched agent is started. The RN does not interpret the genomic report but understands the link between marker and drug well enough to recognize when a result is missing.

Why Suffixes Matter at the Bedside

Suffix recognition is not trivia; it predicts the entire safety conversation. A -mab signals an antibody given parenterally with infusion-reaction readiness; a -nib signals an oral kinase inhibitor with adherence, food, and interaction teaching; a -zomib (bortezomib, carfilzomib) signals neuropathy and a need for herpes-zoster prophylaxis; a -parib signals cytopenias and reproductive precautions; a -ciclib signals neutropenia and liver monitoring.

Brand names should never replace generic names in teaching, because patients encounter both in portals, pharmacy labels, and emergency records, and confusion between the two is a documented source of duplicate dosing and missed interactions. CAR T-cell and bispecific patients also require an emergency wallet card and a caregiver who can drive, because ICANS can impair the patient's ability to recognize or report their own deficit; many programs restrict driving for a defined period after infusion. The nurse confirms a 24-hour contact number and reinforces returning urgently for any fever rather than waiting for additional symptoms.